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Background: Currently, there is still a lack of an optimal treatment for no-reflow phenomenon (NR). The aim of this
simple meta-analysis was to evaluate the efficacy and safety of intracoronary (IC) administration of tirofiban
compared with other conventional drugs during percutaneous coronary intervention (PCI) for NR.
Methods: Systematic literature search was done from PubMed, EMBASE, Google Scholar, EBSCO, Springer and CNKI
databases without language or time limitation. Randomized controlled trials were enrolled for analyzing if they
investigated the treatment of IC administration of tirofiban versus other conventional drugs for NR.
Results: Ten studies with 702 patients were included. Significantly, the treatment of tirofiban was more effective
in improving the thrombolysis in myocardial infarction (TIMI) flow (OR 0.24, 95% CI 0.15-0.37, P < 0.00001) and
reducing major adverse cardiovascular events (MACE) (OR 0.09, 95% CI 0.05-0.18, P < 0.00001). There was a trend to
increase the risk of bleeding, but the data of the result did not reach the statistical significance (OR 1.44, 95% CI
0.69-3.00, P = 0.32).
Conclusions: Tirofiban is more effective than conventional drugs for NR during PCI, but the potential risk of
bleeding complication induced by tirofiban shouldn’t be ignored during clinical practices.Background
Currently, percutaneous coronary intervention (PCI) has
become the most common strategy for acute coronary
syndrome. No-reflow phenomenon (NR) is one of the
serious complications of PCI, which could lead to poor
prognosis [1-3].
The conventional pharmacological treatment for NR
is intracoronary (IC) administration of vasodilators (for
example, adenosine, verapamil, nitroglycerin, sodium
nitroprusside, etc.) [4]. So far, there are some random-
ized controlled trials investigated the treatment of IC
administration of tirofiban for NR. But compared with
conventional drugs, the treatment of tirofiban has not
been evaluated. Therefore, the aim of this article was to
compare the efficacy and safety of IC administration of* Correspondence: cmhnn@sina.com
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reproduction in any medium, provided the ortirofiban with conventional drugs for NR during PCI by
performing a simple meta-analysis.Methods
Search strategy
Completed randomized controlled trials that investigated
the efficacy and safety of IC administration of tirofiban
versus conventional drug for NR during PCI were sought
out by searching the electronic databases, including
PubMed, EMBASE, Google Scholar, EBSCO, Springer
and CNKI. Separate search strategy was developed for
each database using the following keywords: “no-reflow”,
“tirofiban”, “glycoprotein αb/βa inhibitors”, “intracoro-
nary”, “randomized controlled trial” and “percutaneous
coronary intervention”. The search was performed without
language or time limitation. The types of articles such
as comments, letters and the works that were not original
reports were excluded.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study was considered eligible if it met the following cri-
teria: (i) the patients with NR during PCI were enrolled,
(ii) randomly designed patients to a strategy of IC ad-
ministration, either tirofiban or one of the conventional
drugs, (iii) reported at least on one of following out-
comes: transformation of thrombolysis in myocardial in-
farction (TIMI) flow after treatment, major adverse
cardiovascular events (MACE) and bleeding complication.
Methodological quality of the enrolled studies was
assessed in relation to randomization and concealment
of allocation. Quality scale was used to assess the trials:
(A) true randomization and allocation concealed, and (B)
process of randomization not given and concealment of
allocation unclear. This approach was recommended by
the Cochrane Collaboration [5].
Data abstraction
The following information were extracted from the en-
rolled studies: (i) first author’s last name, publication
year, (ii) study design, including the type and dosage of
the IC drugs, duration of treatment, number of patients
and the follow up, (iii) data of endpoints.Figure 1 Search flow diagram of this meta-analysis.Outcome events were based on the definitions used
in the individual trial publications. All data were inde-
pendently extracted by two investigators (TQ and LX).
Results were compared, and disagreements were resolved
by discussion with a third investigator (MHC).Statistical analysis
Data were entered and analyzed using the Cochrane
Collaboration Review Manager software (version 5.2).
The data of outcomes were analyzed separately by indi-
cations (transformation of TIMI flow after treatment,
MACE, bleeding complication). Odds ratios (OR) and
95% confidence intervals (CI) were calculated. Random-
effects models were used since heterogeneity was expected
among the trials. And for unifying the outcomes in forest
plots, we analyzed the incidence of TIMI 0–2 flow trans-
formation after IC treatment, which could also reflex
the incidence of TIMI 3 flow, which was a signal of res-
toration of myocardial perfusion. An OR < 1 suggested
a beneficial effect whilst an OR > 1 suggested a detri-
mental effect. Statistical significance was defined as a
2- sided p value < 0.05.
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Search results
With separate search strategy in each database, the search
yielded 325 articles that were potentially pertinent.
Reviewing titles and abstracts to exclude irrelevant
studies, case reports, editorial comments, and reviews,
42 studies were retrieved for further consideration. Of
the 42 studies, 32 studies were finally excluded mainly
because they only administrated tirofiban additionally
compared with the parallel control group. Ten [6-15]
completed randomized trials fulfilled all the inclusion
criteria and included 702 patients (Figure 1).
Study characteristics
The enrolled studies’ characteristics are presented in
Table 1. The studies published from 2007 to 2012. De-
scribed each study’s characteristic and analyzed the
quality scale. All the trials mentioned randomization
and the comparability of baseline were offered, but not
mentioned the concealment of allocation. After the
quality analyzing, all trials were evaluated B. In the
control group, there were 4 trials administrated with
nitroglycerin [6,9,10,12], 5 with verapamil [7,9,11,14,15]
and 1 with sodium nitroprusside [13].
Quantitative data synthesis
According to the data analysis, all the enrolled trials (n =
702) investigated the transformation of TIMI flow after
the IC pharmacological treatment and the results foundTable 1 Study design of the included randomized controlled
Study N(T/C) Control group Conventional
drugs
Asp Cpg
Chen2012 27/24 √ √ Nitroglycerin 200 μg within 3 min
then IV 0.15 μg/kg•min for 36-48 h
Fu 2012 43/43 √ √ Verapamil 1 mg within 5 mins
Guan 2012 40/40 - - Verapamil 1 mg within 5 mins
He 2012 28/28 √ √ Nitroglycerin 200 μg within 3 min
Luan 2007 45/44 - - Nitroglycerin 200 μg within 3 min
Wang2012 48/34 √ √ Verapamil 200 μg within 15 mins
Wei 2009 26/20 √ √ Nitroglycerin 200 μg within 3 min
then IV 0.15 μg/kg•min for 36-48 h
Wu 2012 36/36 √ √ Sodium nitroprusside 0.9 μg/kg
within 3 mins
Zhang 2010 46/49 √ √ Verapamil 1 mg within 5 mins
Zhang 2012 21/24 √ √ Verapamil 200 μg within 3 mins
§ (1) transformation of TIMI flow, (2) MACE, (3) bleeding complication. *Quality scale
not given and concealment of allocation unclear. Asp, aspirin; Cop, clopidogrel.that tirofiban was more effective in improving the TIMI
flow (OR 0.24, 95% CI 0.15-0.37, P < 0.00001, Figure 2).
Furthermore, tirofiban significantly reduced the MACE
(OR 0.09, 95% CI 0.05-0.18, P < 0.00001, Figure 3), but
had a tendency to increase the risk of bleeding (OR 1.44,
95% CI 0.69-3.00, P = 0.32, Figure 4) in 6 of the 10 trials
(n = 359) [6,9,10,12,13,15].
Specifically, we compared tirofiban with each kind of
conventional drugs for a further analysis of the trans-
formation of TIMI flow. And it also indicated that
tirofiban had its benefit of improving the coronary flow
for NR (OR 0.24, 95% CI 0.15-0.37, P = 0.001, Figure 5).
Discussion
NR could be defined as the persistence of reduced flow
and regional myocardial dysfunction after the removal of
an experimental epicardial coronary occlusion [16].
So far, the precise mechanisms of NR have not been
fully clarified. The optimal therapy for NR is still being
explored. Some studies [17-19] suggested that the dys-
function of coronary microcirculation perfusion was the
central mechanism of NR. And it would not occur until
the lesion of coronary microvascular endothelium to a
certain extent. It was a dynamic and persistent proced-
ure. Once the phenomenon occurred, the inflammation
and lesion of coronary microvascular endothelium would
be aggravated and the effect would sustain for weeks. A
case report [20] showed that the phenomenon could be
improved by taking appropriate intervention measurestrials
Tirofiban Endpoints§ Follow up Quality*
s 10 μg/kg within 3 mins then IV
0.15 μg/kg•min for 36-48 h
(1)(2)(3) 30d B
10 μg/kg within 5 mins then IV
0.075 μg/kg•min for 24 h
(1) - B
10 μg/kg within 5 mins then IV
0.075 μg/kg•min for 24 h
(1) - B
s 10 μg/kg within 3 mins then IV
0.15 μg/kg•min for 24-48 h
(1)(2)(3) 14d B
s 10 μg/kg within 3 mins (1)(2)(3) 7d B
10 μg/kg within 5 mins then IV
0.15 μg/kg•min for 38 h
(1) - B
s 10 μg/kg within 3 mins then IV
0.15 μg/kg•min for 36-48 h
(1)(2)(3) 30d B
10 μg/kg within 3 mins then IV
0.15 μg/kg•min for 24 h
(1)(2)(3) 14d B
10 μg/kg within 5 mins then IV
0.075 μg/kg•min for 24 h
(1) - B
10 μg/kg within 3 mins then IV
0.15 μg/kg•min for 36-48 h
(1)(2)(3) 30d B
: A, true randomization and allocation concealed; B, process of randomization
Figure 2 Forest plot of OR for TIMI flow transformation.
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rapidly could be achieved by removing the microvascular
obstruction and recovering the antegrade coronary flow
of occlusive vessel, and it has become a key of the treat-
ment for NR [21].
For NR, the mechanism of conventional drugs was
mainly for expanding the coronary vessel, which might
be beneficial to allowing the formed microthrombus to
get through the microvascular network and removing
the coronary occlusion. On the basis of the mechanisms,
conventional drugs could not inhibit the sustained thrombi
caused by platelet aggregation when balloon was dilat-
ing, which limited the effect [22,23]. The effects of
these vasodilators in patients with NR were contradict-
ory and could not be sustained by large scale clinical
evidence [24-29].
Platelet aggregation plays an important role in the for-
mation of embolization. Glycoprotein ΙΙb/ΙΙΙa inhibitors
(GPI) block the final pathway of platelet aggregation,
combine with the glycoprotein ΙΙb/ΙΙΙa receptors select-
ively and inhibit the thrombinogen I competitively.
And also, GPI could inhibit the activation, adhesion
and aggregation of platelet. The pharmacological mech-
anisms of GPI were contributed to the formation of
platelet thrombi, restoration the antegrade coronary
flow of occlusive vessel and reducing the incidence of
the ischemia event [30,31]. From the recent researches,
GPI has its obvious advantages in inhibiting the formationFigure 3 Forest plot of OR for MACE.of platelet thrombus, but bleeding event was the main
complication [31,32]. Tirofiban is one kind of GPI, which
with high selectivity and short-acting pharmacological
mechanism [33]. During PCI, IC administration of tiro-
fiban might increase the local drug concentration and
improve the coronary flow. Considering the particular
mechanism, tirofiban selectively blocks the final path-
way of the platelet aggregation, which might contribute
to the improving TIMI flow. And the short half-life
might relative to the reducing of MACE.
Also, the bleeding event needs to be considered. By
analyzing the enrolled trials of this article, 9 of the 10
trials had the administration of tirofiban by intravenous
(IV) infusion after PCI with some degrees. Chen and
Wei administrated both group with IV infusion [6,12],
while the other seven trials only with the tirofiban group
[7-9,11-15]. Although it didn’t reach the statistical sig-
nificance, an increasing trend of bleeding was observed
comparing with the conventional drugs. One of the pos-
sible explanations might be that IV infusion of tirofiban
increased the drug concentration in the system and de-
creased the function of platelet which led to the bleeding
complication. Kimmelstiel et al. [34] referred that the
half-life of tirofiban was 2 hours, and the function of
platelet could recover 89% of the baseline and the pro-
thrombin time recovered completely after 2–4 hours of
the drug withdrawal. In a study by Zhang WZ et al. [35]
of IC administration tirofiban for NR, if the effect was
Figure 4 Forest plot of OR for the risk of bleeding complication.
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for 24-hour post-operation could improve the antegrade
coronary flow of occlusive vessel. But from a meta-
analysis by Geeganage C et al. [36], it suggested that the
additional IV administration of GPI increased the bleed-
ing event. However, the administration of post-operative
IV infusion of tirofiban for NR, whether or how it should
be, needs to be confirmed by further clinical investigations.
Study limitations
Though TIMI is a classical indicator of reperfusion during
PCI [37-39], it doesn’t mean that TIMI 3 flow repre-
sents a normal myocardial perfusion [40]. In other
words, myocardial blush grade (MBG) 0–1 might occur
in the patients with TIMI 3 flow during PCI. It had
been found that MBG was an independent predictor ofFigure 5 Forest plot of OR for TIMI, compared tirofiban with each kinlong-term mortality and could be used to describe the
effectiveness of myocardial reperfusion [41]. Van’t Hof
et al. [42] proposed that the angiographic definition of
successful reperfusion should include both TIMI 3 flow
as well as MBG 2 or 3. Moreover, Stone et al. [43] sug-
gested that MBG could be used to stratify prognosis of
survival in high risk patients achieving TIMI 3 flow
after intervention. Theoretically, MBG is superior to
TIMI when assessing the myocardial perfusion during
PCI. Unfortunately, we didn’t use MBG as an indicator in
the present study, because only one of the ten enrolled
studies provided the data of TIMI as well as MBG in the
comparison of trofiban versus verapamil [7].
As all the enrolled trials’ quality scales were B and
with small sample data, the bias should not be ignored.
Also, the condition of patients, the time and dosage ofd of conventional drugs.
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conventional drugs might have influenced the outcomes.
Therefore, it needs further powerful randomized trials
to investigate the treatment.
Conclusions
The treatment of IC administration of tirofiban is more
effective than the conventional drugs for NR, but the
potential risk of bleeding complication induced by the
drug shouldn’t be ignored during clinical practices.
From this meta-analysis, it suggested that the safety of
IC administration of tirofiban for NR should be fully
considered the individuation of patients and balanced
the efficacy and the hazard.
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